Arich Enterprise Co., Ltd. (4173) AI Stock Analysis

Arich Enterprise Co., Ltd.

(TPEx:4173)

Select Model

Rating:61Neutral

Price Target:TWD 19.00▲(5.56% Upside)

Action:initiatedcoverage

Date:11/09/26

Moderate financial performance is the primary driver, limited by cash flow volatility despite revenue stability and low leverage. Mildly positive technical momentum and a strong dividend yield provide secondary support.

Positive Factors

Steady Revenue ExpansionSteady multi-year revenue expansion indicates sustained demand for the company’s laboratory and IVD offerings. The stronger 2025 step-up can support operating scale, reinforce customer relationships, and provide a durable base for future earnings even if growth moderates.

Negative Factors

Highly Volatile Cash GenerationThe sharp reversal from strong positive cash generation to a very large 2025 outflow makes funding capacity difficult to rely on. If this volatility persists, cash absorption could constrain investment, increase reliance on financing, and weaken liquidity through the coming quarters.

Arich Enterprise Co., Ltd. (4173) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.34B
Dividend Yield: 5.78%
Average Volume (3M): 53.51K
Price to Earnings (P/E): 21.2
Beta (1Y): 0.16
Revenue Growth: 10.77%
EPS Growth: -35.84%
Country: TW
Employees: 198
Sector: General
Sector Strength: 55
Industry: Medical - Distribution

Arich Enterprise Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 1969 and headquartered in New Taipei City, Taiwan, Arich Enterprise Co., Ltd. specializes in the marketing, promotion, and distribution of pharmaceutical products across Taiwan. Their portfolio includes both prescribed medications and...

Arich Enterprise Co., Ltd. Financial Statement Overview

Summary

Steady revenue growth and conservative leverage with low debt-to-equity are offset by extreme cash flow volatility and inconsistent working capital management.

Income Statement

65Positive

Balance Sheet

70Positive

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.56B	1.55B	1.30B	1.14B	1.02B	945.66M
Gross Profit	295.56M	310.63M	252.94M	233.49M	206.77M	207.68M
EBITDA	132.40M	168.86M	164.16M	149.03M	125.63M	114.45M
Net Income	59.55M	86.79M	93.86M	76.53M	62.62M	55.30M
Balance Sheet
Total Assets	5.18B	5.26B	7.10B	5.62B	4.94B	4.49B
Cash, Cash Equivalents and Short-Term Investments	833.00M	793.29M	2.34B	576.58M	707.09M	610.41M
Total Debt	396.05M	633.95M	128.65M	328.98M	64.48M	164.76M
Total Liabilities	3.29B	3.25B	5.18B	3.60B	3.06B	2.67B
Stockholders Equity	1.89B	2.01B	1.92B	2.02B	1.88B	1.82B
Cash Flow
Free Cash Flow	-58.90M	-1.91B	2.14B	-303.35M	116.85M	322.93M
Operating Cash Flow	-36.85M	-1.91B	2.15B	-274.45M	139.23M	336.06M
Investing Cash Flow	-46.20M	-43.71M	-68.49M	-68.54M	48.76M	30.41M
Financing Cash Flow	112.14M	408.71M	-407.12M	206.40M	-77.51M	-197.67M

Arich Enterprise Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4173 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6649	64Neutral	TWD 1.51B	45.55	―	2.81%	-24.55%	-85.90%
TW:6637	62Neutral	TWD 1.46B	10.00	―	8.24%	-13.07%	-26.73%
TW:4161	61Neutral	TWD 1.22B	11.45	―	3.32%	7.54%	35.87%
TW:4173	61Neutral	TWD 1.33B	21.18	―	5.78%	10.77%	-35.84%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

TW:4173 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4173	Arich Enterprise Co., Ltd.	18.00	-2.69	-13.02%
TW:4161	Bioptik Technology, Inc.	21.10	-4.50	-17.57%
TW:6637	Medical Imaging Corp.	54.60	-21.98	-28.70%
TW:6649	Taiwan Biomaterial Co., Ltd.	35.65	-14.07	-28.30%
TW:6847	PuriBlood Medical Co.,Ltd.	70.40	0.11	0.16%
TW:6857	Acer Medical Inc.	89.90	-28.60	-24.14%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Arich Enterprise Co., Ltd. AI Stock Analysis